SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Novo Nordisk A/S (NONOF) 当前追踪市盈率 (P/E) 为 1.7, 前瞻市盈率为 1.9. 追踪盈利收益率为 59.17%, 前瞻盈利收益率 53.19%. PEG 1.13.
本页证实的标准:
- VALUE (100/100, 通过) — 市盈率低于市场平均水平 (1.7); 盈利收益率超过债券收益率 (59.17%).
- PEG 比率 1.13 — 介于1.0–2.0之间，表明相对于增长的估值适中。
- 追踪盈利收益率 59.17% — 超过典型债券收益率（约4.3%），使股票相对固定收益更具吸引力。
SharesGrow 综合评分： 87/100 其中 6/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
100/100
Price-to-Earnings & upside
Proven by this page
~
健康
50/100
Debt-to-Equity & liquidity
→ Health
估值概览 — NONOF
估值倍数
P/E (TTM)1.7
前瞻 P/E1.9
PEG 比率1.13
前瞻 PEG0.24
P/B 比率0.00
P/S 比率0.56
EV/EBITDA0.0
每股数据
EPS (TTM)$22.98
前瞻 EPS（预估）$20.68
每股账面价值$0.00
每股营收$69.33
每股自由现金流$0.00
收益率与内在价值
盈利收益率59.17%
Forward Earnings Yield53.19%
股息收益率0.00%
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2016 |
$7.48 |
$111.78B |
$37.93B |
33.9% |
| 2017 |
$7.70 |
$111.7B |
$38.13B |
34.1% |
| 2018 |
$3.99 |
$111.83B |
$38.63B |
34.5% |
| 2019 |
$4.10 |
$122.02B |
$38.95B |
31.9% |
| 2020 |
$9.01 |
$126.95B |
$42.14B |
33.2% |
| 2021 |
$10.37 |
$140.8B |
$47.76B |
33.9% |
| 2022 |
$12.22 |
$176.95B |
$55.53B |
31.4% |
| 2023 |
$9.31 |
$232.26B |
$83.68B |
36% |
| 2024 |
$22.64 |
$290.4B |
$100.99B |
34.8% |
| 2025 |
$22.98 |
$308.36B |
$102.2B |
33.1% |
